(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 17.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Amicus Therapeutics's revenue in 2025 is $571,160,000.On average, 12 Wall Street analysts forecast FOLD's revenue for 2025 to be $197,239,293,029, with the lowest FOLD revenue forecast at $187,135,206,349, and the highest FOLD revenue forecast at $206,168,987,694. On average, 12 Wall Street analysts forecast FOLD's revenue for 2026 to be $239,107,447,199, with the lowest FOLD revenue forecast at $222,508,756,909, and the highest FOLD revenue forecast at $252,676,144,443.
In 2027, FOLD is forecast to generate $284,021,006,385 in revenue, with the lowest revenue forecast at $257,669,622,302 and the highest revenue forecast at $309,472,331,496.